Previous studies suggest that low prostate weight is a significant negative prognostic factor for prostate cancer. In the current study, the data for 431 men who underwent radical retropubic prostatectomy between 1990 and 1998 Pathologic evaluation of retropubic radical prostatectomy specimens has an essential role in the selection of adjuvant therapy for patients with clinically localized prostate cancer. Surgical margin status, pathologic stage, and Gleason score each has independent prognostic significance for postoperative patients. Prostate size may be clinically assessed by digital rectal examination (DRE) or by transrectal ultrasound (TRUS), so this measurement would be a valuable preoperative prognostic tool if a significant correlation were to exist between prostate size and clinical outcome. Although TRUS correlates more accurately with final prostate weight, DRE and TRUS are routinely used to estimate prostate size in the workup of a patient with prostate cancer. Thus, if prostate weight were related to pathologic variables or risk of recurrence, estimated gland size could be used not only to provide the patient with prognostic information but also to plan surgical strategy and to anticipate radiotherapy needs. Prognostic information based on prostate size or estimated weight would be a valuable noninvasive clinical staging tool.
Pathologic evaluation of retropubic radical prostatectomy specimens has an essential role in the selection of adjuvant therapy for patients with clinically localized prostate cancer. Surgical margin status, pathologic stage, and Gleason score each has independent prognostic significance for postoperative patients. Prostate size may be clinically assessed by digital rectal examination (DRE) or by transrectal ultrasound (TRUS), so this measurement would be a valuable preoperative prognostic tool if a significant correlation were to exist between prostate size and clinical outcome. Although TRUS correlates more accurately with final prostate weight, DRE and TRUS are routinely used to estimate prostate size in the workup of a patient with prostate cancer. Thus, if prostate weight were related to pathologic variables or risk of recurrence, estimated gland size could be used not only to provide the patient with prognostic information but also to plan surgical strategy and to anticipate radiotherapy needs. Prognostic information based on prostate size or estimated weight would be a valuable noninvasive clinical staging tool.
Materials and Methods
A total of 431 men underwent retropubic radical prostatectomy and bilateral pelvic lymphadenectomy between 1990 and 1998 at Indiana University Medical Center, Indianapolis. None of the patients received preoperative radiation or hormone therapy. The prostate weight for each patient was retrieved from the radical prostatectomy specimen examination. Clinical records were reviewed for patient age, preoperative prostate-specific antigen (PSA) level, postoperative PSA level, and evidence of recurrence. The average length of follow-up was 52 months (range, 1.5-180 months). Patients were followed up every 6 months for 2 years and then at annual intervals, as described previously. [1] [2] [3] [4] [5] [6] [7] [8] [9] Patients with pathologic stage T1c were excluded because the low risk of biochemical recurrence in these patients may have obscured any effect of prostate weight on the outcome from clinically significant disease. No patient was excluded because of early recurrence or failure to attain complete PSA remission.
Microscopic evaluation of the radical prostatectomy specimens and the Gleason grading were undertaken by 1 genitourinary pathologist (L.C.). Prostate glands were inked with different colors to distinguish right and left, the glands were weighed after removal of the seminal vesicles, and the prostate was not trimmed of periprostatic soft tissue and bladder neck tissue. The apex and base were amputated and serially sectioned at 3-to 5-mm increments in the vertical parasagittal plane. Each seminal vesicle was amputated and serially sectioned with representative samples submitted for histologic examination. The remainder of the prostate was sectioned at 4-mm increments perpendicular to the long axis from the apex to the bladder base. Representative sections from each quadrant were submitted for microscopic analysis.
The tumors were graded according to the Gleason grading system and staged according to the 2002 American Joint Committee on Cancer TNM grading system. 10 Tumor volume was reported as the estimated percentage of prostate tissue involved by cancer, as described previously. 3, [6] [7] [8] [9] The median of these volume estimates was 20% of the prostatic tissue replaced by tumor. For analytic purposes, tumor volume was considered a dichotomous variable with low-volume disease having less than 20% and high-volume disease having 20% or more malignant tissue in the gland. Surgical margins were considered positive when cancer cells were in contact with the inked margin. 8, [11] [12] [13] Biochemical recurrence was defined as a PSA level greater than 0.2 ng/mL (0.2 μg/L) on 2 postoperative measurements. Approval for retrospective analysis of anonymized patient data was obtained from the institutional review board.
All statistical analyses were conducted using SAS software, version 9.1 (SAS Institute, Cary, NC). The effect of a predictor on PSA recurrence was assessed at the α level of .05. Patient age, Gleason score, prostate weight, and tumor volume were evaluated as continuous variables. Preoperative PSA level, postoperative recurrence, pathologic stage, extraprostatic extension, perineural invasion, high-grade prostatic intraepithelial neoplasia, and lymph node metastasis were evaluated as categorical variables. Prostate weight was also analyzed as a categorical variable, as in previous studies relating prostate weight to pathologic and clinical outcome. 14 Univariate analysis and multiple Cox regression analysis were performed. The effects of prostate weight and of other variables on time to PSA recurrence were assessed by univariate analysis. Variables that were significant at an α of .1 were included in the Cox regression analysis. Using a manual stepwise procedure, only predictors with a P value less than .05 remained in the final model. In 300 patients, the pathologic stage was T2 (69.6%) and in 131 (30.4%) it was T3. The mean weights of the prostates in these 2 groups were 49.8 and 51.6 g, respectively. Of the 431 patients, 34.8% had positive surgical margins, 27.1% had extraprostatic extension, 78.4% had perineural invasion, 3.5% had positive lymph nodes, and 97.0% had high-grade prostatic intraepithelial neoplasia. In addition, 34.3% of the patients had tumor occupying less than 20% of the gland, and 81.9% had a Gleason score of 7 or less. There was no significant association between prostate weight and any of these pathologic variables (Table 1) .
Results

Descriptive
In univariate Cox regression analysis, preoperative PSA levels, positive surgical margins, extraprostatic extension, Gleason score, perineural invasion, and tumor volume were significant predictors of time to recurrence (all P < .05). In the final Cox multiple regression analysis, however, only preoperative PSA level and Gleason score were needed to predict PSA recurrence ❚Table 2❚. Furthermore, when the 4 independent variables of Gleason grade, preoperative PSA level, age, and prostate weight were tested against prognosis-related dependent variables of stage, margin status, and grade, only Gleason score and preoperative PSA level were significantly related to these outcomes ❚Table 3❚. Age and prostate weight showed no significant correlation with the dependent variable. Current study Freedland et al study ❚Figure 1❚ Distribution of prostate weight in 431 patients who underwent radical prostatectomy for prostate cancer in current study. The data were compared with those in a previous study (Freedland et al 14 ) . We also analyzed our data using a simple linear regression model with prostate weight as a categorical variable. The prostate weights were grouped in categories of less than 20 g, 20 to less than 40 g, 40 to less than 60 g, 60 to less than 80 g, 80 to less than 100 g, and 100 g or more. 14 Results remained the same for univariate and multivariate analyses when prostate weight was entered as a categorical variable.
Discussion
Because prostate size is easily measured by noninvasive means, such as TRUS, 15, 16 this parameter would be valuable for choosing optimal therapy if it could predict outcome as suggested in some recent studies. 14, [17] [18] [19] [20] [21] Unfortunately, studies relating prostate weight to outcome have had conflicting results. Some studies have evaluated clinical outcomes in patients with peripheral zone cancer and found no difference in recurrence rates between groups with large or small prostate glands. 22 In the current study, we found that prostate weight increased significantly in older patients. This is an expected finding and makes intuitive sense. The association between prostate weight and age is well established. [23] [24] [25] We also found that patients with high preoperative PSA levels had larger prostate glands at the time of their prostatectomy. PSA is produced by both benign and malignant prostate tissue, so one would expect larger glands to produce more PSA simply owing to their increased volume. There was no association between prostate weight and PSA recurrence. This finding diverges from a recent study in which patients with smaller glands had a higher risk of biochemical recurrence and proposed that prostate size be used as a preoperative and postoperative prognostic marker. 14 Another study presented nomograms for predicting indolent carcinomas based on serum PSA level, primary and secondary Gleason pattern scores, TRUS estimation of the prostate size, and proportion of cancer in the biopsy cores. 26, 27 The 409 cases analyzed all had PSA values of less than 20 ng/mL (20 μg/L), no Gleason pattern 4 or 5, and no cores containing greater than 50% cancer. The current study included a representative cross-section of all patients treated with surgery at this institution, including 44 patients (11.8%) with PSA levels of 20 ng/mL (20 μg/L) or more and 277 (64.2%) with a Gleason score of 7 or more.
The relationship between serum PSA measurements and prostate size is complex. Intuitively, one might expect no association between prostate weight and preoperative PSA or a positive correlation based on prostatic enlargement by tumor infiltration. Whether in a large or small prostate, the malignant cells often represent only a small part of the total prostatic tissue. The PSA elevation associated with prostatic malignancy, therefore, may involve stimulation of benign epithelium by malignant cells. It is interesting to note that although only 10% to 20% of prostate carcinomas arise in the transition zone, 28 serum PSA values correlate more closely with tissue volume or epithelial volume in the transition zone than with these measures in the peripheral zone or in the entire prostate. 29 Because the majority of cases in the period of this study (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) were found by PSA screening, a high proportion of all patients with newly diagnosed prostate cancer had resectable tumors at diagnosis. Because hyperplastic and neoplastic prostatic epithelium produces PSA, benign enlargement with age and increased prevalence of clinically innocuous malignancy with age should both be associated with elevation of serum PSA. [23] [24] [25] Early detection screening is effective because prostate glands with neoplastic epithelium release more PSA than prostate glands with benign epithelium. Nevertheless, patients with PSA elevation due to benign hyperplasia are likely to have small tumors found earlier because the combined PSA elevation triggers biopsy earlier in the course of tumor progression. This may result in a greater lead time bias for patients with greater benign hyperplasia components in their glands. Consequently, because of lead time bias and "overdiagnosis" of small tumors in large glands, it is reasonable to assume that a larger prostate gland would be associated with earlier biopsy and lower probability of recurrence. Although prostate sextant biopsies are essentially random and one could argue that a larger gland should lead to underdiagnosis, studies of biopsy sensitivity have shown no significant decrement with larger prostates. 30 In a recent study of men who underwent prostatectomy at 5 medical centers, patients with smaller glands were found to have a higher risk of biochemical recurrence. 14 In this study, the inverse relationship between prostate size and recurrence risk was present even when cases that were detected solely by PSA elevation (clinical T1c) and cases at the extreme ends of the prostate weight spectrum (>100 g or <20 g) were excluded. 14 However, examination of the Kaplan-Meier curves shows little separation between the outcomes for the majority of patients whose prostate glands weighed between 20 and 100 g, particularly when the early parts of the curves before the median follow-up are examined. The patients without extreme prostate weights represented 93% of the patients in that study and about 94% of the patients in the current study. The mean follow-up interval was 46 months, similar to the follow-up of 52 months in the current study. Moreover, in the study finding a worse prognosis for patients with smaller prostate glands, the investigators analyzed prostate weight as a categorical variable, whereas age and preoperative PSA values were included as continuous variables. Because of the interdependence among these 3 variables, controlling for age and serum PSA level while analyzing the third variable may cause prostate weight to appear as a surrogate for the other 2 parameters.
Another possible explanation is that the prostate weights in this previous study included the seminal vesicles, whereas these were amputated before weighing in the present study. Seminal vesicle size is more difficult to estimate by DRE or TRUS than prostate size. In fact, seminal vesicle size is so clearly related to serum testosterone level that their weight may be used as a bioassay for chronic androgen exposure. 31 Thus, it is possible that in the rare cases when prostate cancer arises in men with small prostate glands and small seminal vesicles, it is more likely to be of the aggressive, androgenindependent variety. This may account for the finding in the series by Freedland et al 14 of high-grade carcinoma in small glands (<20 g). Prostate glands in this size range, however, accounted for only 3% of that study population and represent only about 1% of the glands in the current study.
A limitation of the current study is that representative sections rather than whole-mount slides were used to estimate tumor volume and to evaluate margin status, extracapsular extension, or foci of high-grade cancer. 3, [6] [7] [8] [9] Nevertheless, because the end point of this study was PSA recurrence, underestimation of these prognostic variables should have little effect on the conclusions of the study. Other studies, however, have used a similar representative section procedure, which may have led to a higher probability of finding adverse prognostic observations in smaller prostate glands. [16] [17] [18] [19] [20] [21] Because studies relating prostate size to clinical outcome generally use a relative scale of prostate specimen weight to correlate with clinical outcomes, changes in gland weight by fixation should be proportional in all specimens and, thus, have little impact on the conclusions of the study. There are, however, a variety of surgical techniques for prostatectomy, which may result in different amounts of soft tissue being attached to the prostate specimen and bladder neck. When comparing different studies, one should be careful to specify whether laparoscopic, retropubic, or perineal approaches are used and whether soft tissue is removed before weighing the specimens. All prostatectomy specimens in the current study were obtained by retropubic radical prostatectomy, and care was taken in each case to remove seminal vesicles before weighing the specimen.
The large number of patients needed to demonstrate the purported inverse relationship between prostate size and prognosis is more an indication of the weakness of the supposed effect than a criticism of smaller studies that fail to show this effect. The study by Pierorazio et al 21 demonstrated not higher frequency of PSA recurrence or shorter time to progression, but instead, higher frequency of extracapsular extension and more specimens with positive surgical margins in smaller prostates. Although prostate cancer stage and Gleason grade have steadily improved with better assays and improved screening protocols, the independent prognostic significance of positive margins, extension outside the gland, and seminal vesicle invasion has been unchanged for 2 decades. 32 Proximity of tumor to the capsule of very small glands and a trend toward extracapsular invasion when there is less normal gland tissue may explain the prevalence of these adverse pathologic findings in patients with very small prostate glands. Because positive margins and extracapsular extension are strong predictors of recurrence, increased probability of these risk factors in the smallest prostate set may account for the apparent negative clinical impact of small glands. Nevertheless, the findings of this study do not support using prostate size as a generalized, independent prognostic tool. The study by Pierorazio et al 21 showed not higher stage and grade in smaller glands, but a greater tendency to upstage or to upgrade postoperatively when the gland was small. Even these effects were weak, with odds ratios ranging from 0.99 to 1.03. 21 In the current study, we found no increased risk of PSA recurrence in patients with smaller glands. This may, in part, reflect the relatively large prostate glands and high-grade disease at the time of diagnosis of carcinomas included in this study compared with studies finding a relationship between gland size and clinical prognosis. 14 The mean size of the glands in our series was 50.4 g. This is lower than the average gland size in many other series and could have reduced the lead time bias as described earlier. It is also possible that our series was not carried out for a period long enough to expose any potential delayed recurrence related to small glands because our study had an average follow-up of just more than 4 years. However, there is little difference between our average follow-up of 52 months and the average follow-up period of 46 months in the largest study relating prostate size to PSA recurrence. 14 If lead time bias were to cause a favorable prognosis in patients with extremely large prostates, and tumor characteristics or risk of positive margins were related to an unfavorable prognosis in patients with extremely small prostates, then outcomes in these 2 tails may overshadow random behavior of tumors in the majority of patients. The study by Freedland et al 14 found a significant inverse statistical relationship between prostate size and time to recurrence, even when the extreme groups were excluded, but examination of the Kaplan-Meier curves in that study showed considerable proximity and even overlap of the inner curves, particularly below the median follow-up of 34 months. Moreover, if these 2 trivial influences persist even weakly in the main cohort of patients, then a large study may impart significance or even independence to their apparent ability to predict outcome.
We found no significant relationship between prostate weight and any of the examined pathologic variables. These findings were the opposite of the results reported by Freedland et al, 14 whose data demonstrated a higher incidence of extraprostatic extension and a higher Gleason score among patients with smaller glands. Previous studies have already cited lead time bias as an explanation for the ostensible conclusion that men with larger glands have a better clinical course. However, Freedland et al 14 presented several arguments that speak against a lead time bias. They found that prostate cancers in lower weight glands have higher Gleason grades and more frequently display extraprostatic extension, even after exclusion of stage T1c cases. The rare, aggressive, androgen-independent type of prostatic adenocarcinoma apparently occurs only in men with small prostate glands and small seminal vesicles. Our study excluded stage T1c cases, as explained, because this subset may exaggerate the influence of lead time bias in a study of prostate size. Further investigation is needed to address these discrepancies. Because prostate size is easily evaluated preoperatively, any relationship between size and pathologic outcome would be important to establish definitively. If, however, an inverse relationship between prostate size and prognosis applies mainly for extremely large or small glands, then this parameter should not replace established prognostic variables of preoperative PSA level and biopsy Gleason grade.
